A Phase II Study of Postoperative Radiotherapy With Tyrosine Kinase Inhibitor (Anlotinib) for Resectable Soft Tissue Sarcoma With High Recurrence Risk
Overview
- Phase
- Phase 2
- Intervention
- Anlotinib
- Conditions
- Soft Tissue Sarcoma
- Sponsor
- Ruijin Hospital
- Enrollment
- 41
- Locations
- 1
- Primary Endpoint
- Local Recurrence Free Survival (LRFS)
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma
Detailed Description
Right now, resection and radiotherapy (RT) is the most effective and recommended treatment for soft tissue sarcoma (STS). Local recurrence rate has significantly reduced since the application of RT. However, RT has brought a lot of complications which had disturbed patients' quality of life. Anlotinib is a novel tyrosine kinase inhibitor targeting multiple factors involving tumor proliferation, vasculature, and tumor microenvironment. Anlotinib inhibits VEGF/VEGFR signaling by selectively targeting VEGFR-2,-3 and FGFR-1,-2,-3,-4 with high affinity. Anlotinib also suppresses the activity of PDGFRα/β, c-Kit, Ret, Aurora-B, c-FMS, and discoidin domain receptor 1 (DDR1), leading to significant inhibition of tumor proliferation. In phase I study, anlotinib showed promising antitumor potential against STS. In a phase II study, anlotinib showed antitumor activity in several STS with well tolerant and manageable adverse effect. In this clinical study, investigators will explore the efficacy of Anlotinib combined with dose reduced postoperative radiotherapy on recurrence and metastasis control of STS. Patients with STS would receive standard treatment and recommended dose of radiotherapy. In addition, they will receive anotinib from 3 or 4 weeks after surgery, and continue for 3 months. The primary endpoint is Local Recurrence Free Survival (LRFS).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed and histopathologically confirmed as high histologic grade soft-tissue sarcoma, including undifferentiated pleomorphic sarcoma (UPS), liposarcoma(LPS), leiomyosarcoma (LMS), synovial sarcoma (SS), alveolar soft-part sarcoma (ASPS), clear cell sarcoma (CCS).
- •Upper limb (including shoulder), lower limb (including hip) and pelvic soft-tissue sarcoma,
- •Age ≥ 18 years,
- •High risk of local recurrence was defined if the largest diameter of tumor \>5cm and had at least one of below characters (1) Tumor border close (\<5mm) to vital tissue (vessel and nerve) from diagnostic MRI (2) MRI shows infiltrative tumor grow type ('focal-type' and 'diffuse-type') (3) Positive microscopic margins or macroscopic residual (4) Recurrent tumor form previous treatment High risk of recurrence must be assessed by staff including a surgeon specialized in sarcoma,
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2,
- •Only one lesion, and can be accurately measured at baseline as ≥ 5cm in the longest diameter with magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements according to RECIST 1.1,
- •Adequate hematological, renal, metabolic and hepatic function:
- •Haemoglobin ≥ 9 g/dL and no blood transfusions in the 14 days prior to study entry Absolute neutrophil count (ANc) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Total bilirubin ≤ 1.5 x upper limit of normality (ULN), Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) ≤ 2.5 x ULN, Serum creatinine ≤ 150 μmol/L or creatinine clearance ≥ 50 mL/min (according to local institution) in case of serum creatinine \> 150 μmol/L, TP, INR ≤ 1.5 x ULN
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up,
- •Voluntary signed and dated written informed consent prior to any specific procedure,
Exclusion Criteria
- •Any previous treatment, including chemotherapy, radiotherapy and target therapy, within 6 months from the last time prior to study treatment,
- •Soft-tissue sarcoma occurred at head and neck, visceral organs, retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis
- •Patients with the following entities were excluded: GIST, rhabdomyosarcoma, chondrosarcoma, osteosarcoma, dermatofibrosarcoma protuberans, Ewing sarcoma, primitive neuroectodermal tumor, inflammatory myofibroblastic tumor, and malignant mesothelioma.
- •Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication,
- •Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy,
- •Patients with known active hepatic disease (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids,
- •Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent,
- •Patients with uncontrolled seizures,
- •Women of childbearing potential who are not using an effective method of contraception; women who are pregnant or breast feeding,
- •No prior or concurrent malignant disease diagnosed or treated in the last 2 years,
Arms & Interventions
Surgery + Dose Reduced Radiotherapy + Anlotinib
Surgery would be performed to resect soft tissue sarcoma with as wide margin as possible. Important vessels and nerves should be preserved. Postoperative radiotherapy would be performed. Postoperative intensity-modulated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles).
Intervention: Anlotinib
Surgery + Dose Reduced Radiotherapy + Anlotinib
Surgery would be performed to resect soft tissue sarcoma with as wide margin as possible. Important vessels and nerves should be preserved. Postoperative radiotherapy would be performed. Postoperative intensity-modulated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles).
Intervention: Radiotherapy
Surgery + Dose Reduced Radiotherapy + Anlotinib
Surgery would be performed to resect soft tissue sarcoma with as wide margin as possible. Important vessels and nerves should be preserved. Postoperative radiotherapy would be performed. Postoperative intensity-modulated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles).
Intervention: Surgery
Outcomes
Primary Outcomes
Local Recurrence Free Survival (LRFS)
Time Frame: 36-month
From the time of surgery to the time of local recurrence identified by image examination.
Secondary Outcomes
- Overall Survival (OS)(36-month)
- Metastasis free survival (MFS)(36-month)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](an average of 3 years)